uPAR-directed albumin-based delivery leverages two complementary biological facts to improve drug targeting in breast cancer: uPAR is frequently overexpressed on invasive, chemo-resistant, and cancer stem-like breast tumor cells, driving invasion and Wnt/β-catenin signaling, and albumin is a long-circulating, easily modified carrier that cancer cells avidly scavenge via receptor-mediated routes and macropinocytosis. The gene discussed is PLAUR; the disease is breast neoplasm.